The pharmaceutical company that developed one of the vaccines for COVID-19, AstraZeneca, will partner with a United States-based Artificial Intelligence (AI) biologics firm, Absci, to design an antibody for cancer. 

According to a Financial Times report on Dec. 3, AstraZeneca will invest up to $247 million in research and development, milestone payments and an upfront fee for Absci. The collaboration aims to create a zero-shot generative AI model, which would work on creating new antibody therapeutics for cancer and improving existing ones. The report didn’t specify the type or types of cancer involved.

Related: AI in healthcare. New tech in diagnosis and patient care

Absci’s website…

Read more on Cointelegraph